We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
-7.86%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.17B
AUM Growth
-$939M
(-15%)
Cap. Flow
-$328M
Cap. Flow
% of AUM
-6.34%
Top 10 Holdings %
Top 10 Hldgs %
49.51%
Holding
202
New
57
Increased
36
Reduced
26
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Home Depot
HD
|
+$121M |
| 2 |
PTC Therapeutics
PTCT
|
+$81.6M |
| 3 |
Viatris
VTRS
|
+$76.4M |
| 4 |
Target
TGT
|
+$69.6M |
| 5 |
Five Below
FIVE
|
+$60.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Academy Sports + Outdoors
ASO
|
+$66.3M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$62.3M |
| 3 |
Ulta Beauty
ULTA
|
+$62.1M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$59.8M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$58.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 45.3% |
| 2 | Consumer Staples | 9.22% |
| 3 | Consumer Discretionary | 6.86% |
| 4 | Technology | 3.5% |
| 5 | Communication Services | 1.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $1.08B | 20.96% |
24,000
-4,000
| -14% | -$1.78M |
|
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
| $575M | 11.11% |
28,000
-2,000
| -7% | -$408K |
|
3
Travere Therapeutics
TVTX
$5.33B
| $128M | 2.47% |
4,958,000
+880,000
| +22% | +$23.4M |
|
4
Incyte
INCY
$23.5B
| $121M | 2.34% |
1,524,000
-632,000
| -29% | -$46M |
|
5
Biogen
BIIB
$29.9B
| $120M | 2.33% |
572,000
+112,000
| +24% | +$24.4M |
|
|
6
PTC Therapeutics
PTCT
$6.37B
| $113M | 2.19% |
3,036,000
+2,118,893
| +231% | +$81.6M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $112M | 2.17% |
1,364,000
+528,000
| +63% | +$54M |
|
|
8
Home Depot
HD
$332B
| $105M | 2.03% |
+349,897
| New | +$121M |
|
|
9
Bristol-Myers Squibb
BMY
$127B
| $102M | 1.97% |
1,396,000
-928,000
| -40% | -$62.3M |
|
10
Supernus Pharmaceuticals
SUPN
$2.68B
| $100M | 1.94% |
3,100,000
-1,036,000
| -25% | -$31.8M |
|
11
Madrigal Pharmaceuticals
MDGL
$12.6B
| $96M | 1.86% |
978,000
-146,000
| -13% | -$12.3M |
|
12
Enanta Pharmaceuticals
ENTA
$372M
| $80M | 1.55% |
1,124,000
+68,000
| +6% | +$4.42M |
|
|
13
Jazz Pharmaceuticals
JAZZ
$15.9B
| $73.5M | 1.42% |
472,000
-406,000
| -46% | -$58.9M |
|
|
CPRX
14
DELISTED
Catalyst Pharmaceutical
CPRX
| $69.4M | 1.34% |
8,372,000
-1,200,000
| -13% | -$8.48M |
|
|
15
Target
TGT
$62.1B
| $68.3M | 1.32% |
+321,698
| New | +$69.6M |
|
16
CRISPR Therapeutics
CRSP
$4.58B
| $64.3M | 1.24% |
1,024,000
+132,000
| +15% | +$8.29M |
|
|
17
Viatris
VTRS
$20.1B
| $63.1M | 1.22% |
+5,800,000
| New | +$76.4M |
|
18
argenx
ARGX
$57.4B
| $63.1M | 1.22% |
200,000
+12,000
| +6% | +$3.49M |
|
19
Central Garden & Pet Co Class A
CENTA
$2.41B
| $62.6M | 1.21% |
1,920,000
+585,000
| +44% | +$20.1M |
|
20
Illumina
ILMN
$29.4B
| $62.2M | 1.2% |
182,984
+64,764
| +55% | +$21.9M |
|
|
BHVN
21
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $62.1M | 1.2% |
524,000
+56,000
| +12% | +$6.98M |
|
|
OCDX
22
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $62M | 1.2% |
3,324,000
+2,228,000
| +203% | +$40.1M |
|
23
Kraft Heinz
KHC
$30.4B
| $61.9M | 1.2% |
1,572,000
+208,000
| +15% | +$7.79M |
|
|
24
Vertex Pharmaceuticals
VRTX
$121B
| $61.6M | 1.19% |
236,000
-252,000
| -52% | -$59.8M |
|
25
Neurocrine Biosciences
NBIX
$17.7B
| $60.9M | 1.18% |
+650,000
| New | +$55.1M |
|
Similar funds
CRC
RMDI
F
DWM
DCP
EW
AIM
O
Armistice Capital's Q1 2022 Portfolio in Review
As of Q1 2022, Armistice Capital held 202 positions worth $5.17B, down 15% from $6.11B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Armistice Capital withdrew a net $328M in Q1 2022, closing 61 positions and reducing 26 holdings. Its most notable exit was Academy Sports + Outdoors, an estimated $66.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 43% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, Armistice Capital opened a new position in Home Depot worth $105M.
- Armistice Capital's largest Q1 2022 buy was Home Depot: 349,897 shares worth $105M.
- Armistice Capital added most to PTC Therapeutics in Q1 2022, an estimated $81.6M increase.
- Armistice Capital's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $62.3M.
- Armistice Capital fully exited Academy Sports + Outdoors in Q1 2022, selling an estimated $66.3M.
- Armistice Capital's ten largest holdings make up 50% of its $5.17B portfolio in Q1 2022.
- Armistice Capital opened 57 new positions and closed 61 in Q1 2022.
- Armistice Capital's portfolio value fell 15% quarter-over-quarter to $5.17B.
Based on Armistice Capital's 13F filing for Q1 2022, filed 16 May 2022.